Retail
Celsius revenue surges 11% to $817.9 million
Celsius Holdings (NASDAQ:CELH) reported Q2 2026 revenue of $817.9 million, up 10.6%, with gross margin reaching 48.1%.
United StatesBreaking News
Oil and Gas
Genesis Energy net income reaches $42.9 million
Genesis Energy (NYSE:GEL) reported Q2 2026 attributable net income of $42.9 million, reversing a $0.4 million loss.
Financial
Huntington's Braddock Assesses Bank's Outlook in Texas
Billy Braddock, regional group president at Huntington Bancshares Inc., discusses the bank's business in Texas after taking over Cadence Bank, the loan business in the state and the adoption of artificial intelligence. He speaks with Bloomberg's Julie Fine.
Oil and Gas
Canadian Natural Resources reports $4.5 billion net earnings
Canadian Natural Resources (NYSE:CNQ) reported second-quarter net earnings of $4.5 billion alongside an 18% daily production increase.
Entertainment
Six Flags posts $203 million quarterly loss
Six Flags Entertainment (NYSE:FUN) reported Q2 2026 net revenue of $865 million and a net loss attributable to the company of $203 million.
Health
LifeMD’s $47.3 million revenue result comes with a grim forecast
LifeMD (NASDAQ:LFMD) reported Q2 2026 revenue of $47.3 million and cut its full-year outlook after recording a $3.5 million adjusted EBITDA loss.
Mining
McEwen delivers a major profit jump to $9.6 million
McEwen (NYSE:MUX) reported Q2 2026 net income of $9.6 million, or $0.16 per share.
Mining
Fortuna second quarter revenue rallies 38% to $318.4 million
Fortuna (NYSE:FSM) reported Q2 2026 sales of $318.4 million, up 38%, and adjusted EBITDA of $200.8 million.
Health
Moderna receives FDA approval for mFLUSIVA flu vaccine
Moderna (NASDAQ:MRNA) received U.S. FDA approval for mFLUSIVA, an mRNA-based seasonal influenza vaccine for adults over 50.
Technology
United Microelectronics Corporation reports NT$23.8 billion July sales
United Microelectronics Corporation (NYSE:UMC) reported NT$23.84 billion in July 2026 unaudited net sales.
Health
Evotec signs AI drug discovery partnership
Evotec (NASDAQ:EVO) entered a research partnership with Odyssey Therapeutics (NASDAQ:ODTX) to identify small-molecule candidates for autoimmune and inflammatory diseases.
Financial
'Reasonable' to Allocate in US Given Earnings, Wytenus Says
Erik Wytenus, EMEA head of investment strategy at JPMorgan Private Bank, says robust earnings make it "reasonable to continue to allocate to a healthy degree to the US." He speaks on Bloomberg Television.